Surface Logix Achieves Objectives With SLx-2101 In Phase 2a Clinical Trial In Hypertension

Surface Logix announced positive results in the Company’s Phase 2a clinical trial of SLx-2101 in hypertension. The randomized, double-blind, placebo-controlled crossover Phase 2a study in 60 patients with uncontrolled hypertension demonstrated that SLx-2101 caused clinically significant reductions in blood pressure and was well tolerated.

More: continued here

Filed under: Clinical Trials on January 9th, 2008